Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 112.5K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge, Masakazu Toi, Patrick Neven et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +10

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

Nadia Howlader, Sean F. Altekruse, Christopher I. Li et al. · JNCI Journal of the National Cancer Institute · 2014 · 1.5K citations · Full text

Medicine, Oncology, Cancer Epidemiology +13

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17